Please login to the form below

Not currently logged in
Email:
Password:

Dapagliflozin meets goals of late-stage study

Bristol-Myers Squibb and AstraZeneca's diabetes drug dapagliflozin has met the main goals of a phase III trial

BMS and AZ's diabetes drug dapagliflozin met the main goals of a phase III trial. It was proven that the drug was more effective than an older treatment at reducing blood sugar levels.

Dapagliflozin is a first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor being developed as a once-daily oral therapy for the treatment of adult patients with type 2 diabetes.

The trial enrolled 597 patients with type 2 diabetes that was inadequately controlled with at least half the recommended dose of glimepiride. The companies said a combination of dapagliflozin and glimepiride was better at reducing blood sugar levels than glimepiride and a placebo.

Patients on dapagliflozin also lost more weight, had greater oral glucose tolerance and lower blood sugar levels between meals after the 24-week late stage clinical trial.

Side-effects were similar for dapagliflozin and glimepiride, but patients on dapagliflozin were more likely to have genital tract infections.

Results from the trial were presented at a meeting of the European Association for the Study of Diabetes in Stockholm.

21st September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Article: What's next? How behavioural science can support pharma's future
...

Infographics